| Market Capitalization (Millions $) |
6,385 |
| Shares
Outstanding (Millions) |
22 |
| Employees |
53 |
| Revenues (TTM) (Millions $) |
77 |
| Net Income (TTM) (Millions $) |
-519 |
| Cash Flow (TTM) (Millions $) |
176 |
| Capital Exp. (TTM) (Millions $) |
7 |
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of serious diseases that are impacting the lives of patients around the world. The company was founded in 2011 with the goal of using its expertise in the field of liver metabolism to develop novel drugs that can help patients with various forms of liver and cardiovascular diseases.
The company's flagship product is MGL-3196, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from non-alcoholic steatohepatitis (NASH), a serious liver disease that is characterized by inflammation and the accumulation of fat in the liver. The drug has shown significant promise in early clinical trials, and it is currently being evaluated in phase 3 clinical trials for the treatment of NASH.
Madrigal is also developing other products that are designed to address other liver and cardiovascular diseases. One of the company's other products is MGL-3745, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from dyslipidemia. Dyslipidemia is a condition that is characterized by high levels of cholesterol and triglycerides in the blood, which can lead to serious health problems such as heart disease and stroke.
In addition to its drug development efforts, Madrigal is also actively engaged in research and development activities aimed at discovering new and innovative therapies for other serious diseases. The company has a team of experienced researchers and scientists who are working to identify new drug targets and develop new drug candidates that can help patients suffering from a range of diseases.
Overall, Madrigal Pharmaceuticals Inc. is a highly innovative and promising biopharmaceutical company that is focused on developing new and effective treatments for serious diseases. With its focus on liver and cardiovascular diseases and its highly experienced team of researchers and scientists, the company is well-positioned to make a significant impact on the lives of patients around the world.
Company Address: Four Tower Bridge West Conshohocken 19428 PA
Company Phone Number: 824-2827 Stock Exchange / Ticker: NASDAQ MDGL
|
1.68%